{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:21:59Z","timestamp":1783952519244,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HR21C0198"],"award-info":[{"award-number":["HR21C0198"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C2091689"],"award-info":[{"award-number":["2022R1A2C2091689"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2024IP0076"],"award-info":[{"award-number":["2024IP0076"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-026-02390-x","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:35:21Z","timestamp":1778913321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term safety and efficacy of triheptanoin in Korean patients with long-chain fatty acid oxidation disorders: a prospective, open-label, single-center, phase II clinical study"],"prefix":"10.1186","volume":"19","author":[{"given":"Ji-Hee","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Hye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjae","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"24","key":"2390_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.21037\/atm.2018.10.57","volume":"6","author":"JL Merritt","year":"2018","unstructured":"Merritt JL, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2390_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11154-018-9448-1","volume":"19","author":"SJG Knottnerus","year":"2018","unstructured":"Knottnerus SJG, Bleeker JC, Wust RCI, Ferdinandusse S, L IJ, Wijburg FA, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93\u2013106.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2390_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11154-020-09568-3","volume":"21","author":"JL Merritt 2nd","year":"2020","unstructured":"Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020;21(4):479\u201393.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2390_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10545-009-1126-8","volume":"32","author":"U Spiekerkoetter","year":"2009","unstructured":"Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32(4):498\u2013505.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 7","key":"2390_CR5","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.37765\/ajmc.2020.88480","volume":"26","author":"J Vockley","year":"2020","unstructured":"Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020;26(Suppl 7):S147\u201354.","journal-title":"Am J Manag Care"},{"issue":"5","key":"2390_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10545-012-9542-6","volume":"36","author":"J Baruteau","year":"2013","unstructured":"Baruteau J, Sachs P, Broue P, Brivet M, Abdoul H, Vianey-Saban C, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36(5):795\u2013803.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2390_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10545-009-9001-1","volume":"33","author":"B Wilcken","year":"2010","unstructured":"Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010;33(5):501\u20136.","journal-title":"J Inherit Metab Dis"},{"key":"2390_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-6-44","volume":"6","author":"M Lindner","year":"2011","unstructured":"Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases\u2013report of 10 years from South-West Germany. Orphanet J Rare Dis. 2011;6:44.","journal-title":"Orphanet J Rare Dis"},{"issue":"2\u20133","key":"2390_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10545-006-0320-1","volume":"29","author":"H Brunengraber","year":"2006","unstructured":"Brunengraber H, Roe CR. Anaplerotic molecules: current and future. J Inherit Metab Dis. 2006;29(2\u20133):327\u201331.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2390_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jimd.12313","volume":"44","author":"J Vockley","year":"2021","unstructured":"Vockley J, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. J Inherit Metab Dis. 2021;44(1):253\u201363.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2390_CR11","doi-asserted-by":"publisher","first-page":"E860","DOI":"10.1152\/ajpendo.00366.2005","volume":"291","author":"RP Kinman","year":"2006","unstructured":"Kinman RP, Kasumov T, Jobbins KA, Thomas KR, Adams JE, Brunengraber LN, et al. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am J Physiol Endocrinol Metab. 2006;291(4):E860\u20136.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1\u20132","key":"2390_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ymgme.2015.06.006","volume":"116","author":"J Vockley","year":"2015","unstructured":"Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, et al. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment: A retrospective chart review. Mol Genet Metab. 2015;116(1\u20132):53\u201360.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2390_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ymgme.2017.02.005","volume":"120","author":"J Vockley","year":"2017","unstructured":"Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, et al. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment. Mol Genet Metab. 2017;120(4):370\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2390_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jimd.12038","volume":"42","author":"J Vockley","year":"2019","unstructured":"Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, et al. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2019;42(1):169\u201377.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"2390_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10545-017-0085-8","volume":"40","author":"MB Gillingham","year":"2017","unstructured":"Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831\u201343.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2390_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/jimd.12640","volume":"46","author":"J Vockley","year":"2023","unstructured":"Vockley J, Burton BK, Berry G, Longo N, Phillips J, Sanchez-Valle A, et al. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study. J Inherit Metab Dis. 2023;46(5):943\u201355.","journal-title":"J Inherit Metab Dis"},{"key":"2390_CR17","unstructured":"U.S. Food and Drug Administration. Guidance for industry: safety reporting requirements for investigational new drugs (INDs) and bioavailability\/bioequivalence studies. Silver Spring: U.S. Food and Drug Administration; 2012."},{"key":"2390_CR18","unstructured":"U.S. Food and Drug Administration. Guidance for industry: investigator responsibilities\u2014protecting the rights, safety, and welfare of study subjects. Silver Spring: U.S. Food and Drug Administration; 2009."},{"key":"2390_CR19","volume-title":"Manual for the child behavior checklist and revised child behavior profile","author":"TM Achenbach","year":"1983","unstructured":"Achenbach TM, Edelbrock CS. Manual for the child behavior checklist and revised child behavior profile. Burlington: University Associates in Psychiatry; 1983."},{"key":"2390_CR20","first-page":"138","volume":"2","author":"H Lee","year":"1991","unstructured":"Lee H, Oh KJ, Hong KE, Ha EH. Clinical validity study of Korean CBCL through item analysis. J Korean Acad Child Adolesc Psychiatry. 1991;2:138\u201349.","journal-title":"J Korean Acad Child Adolesc Psychiatry"},{"issue":"8","key":"2390_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"key":"2390_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1477-7525-6-41","volume":"6","author":"SH Kook","year":"2008","unstructured":"Kook SH, Varni JW. Validation of the Korean version of the pediatric quality of life inventory 4.0 (PedsQL) generic core scales in school children and adolescents using the Rasch model. Health Qual Life Outcomes. 2008;6:41.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2390_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"2390_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561\u201371.","journal-title":"Arch Gen Psychiatry"},{"key":"2390_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-5-54","volume":"5","author":"SS Farivar","year":"2007","unstructured":"Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes. 2007;5:54.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2390_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","volume":"3","author":"JW Varni","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329\u201341.","journal-title":"Ambul Pediatr"},{"issue":"2","key":"2390_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2022.04.001","volume":"136","author":"J Vockley","year":"2022","unstructured":"Vockley J, Enns GM, Ramirez AN, Bedrosian CL, Reineking B, Lu X, et al. Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program. Mol Genet Metab. 2022;136(2):152\u201362.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2390_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00431-025-06216-3","volume":"184","author":"E Kose","year":"2025","unstructured":"Kose E, Inci A, Yazici H, Zubarioglu T, Kilavuz S, Ciki K, et al. The effect of triheptanoin treatment on clinical and laboratory outcomes in patients with long-chain fatty acid oxidation disorder. Eur J Pediatr. 2025;184(6):382.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2390_CR29","doi-asserted-by":"publisher","first-page":"e2037227","DOI":"10.1001\/jamanetworkopen.2020.37227","volume":"4","author":"JH Pelletier","year":"2021","unstructured":"Pelletier JH, Rakkar J, Au AK, Fuhrman D, Clark RSB, Horvat CM. Trends in US pediatric hospital admissions in 2020 compared with the decade before the COVID-19 pandemic. JAMA Netw Open. 2021;4(2):e2037227.","journal-title":"JAMA Netw Open"},{"key":"2390_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jpeds.2022.08.060","volume":"254","author":"A Ouattara","year":"2023","unstructured":"Ouattara A, Resseguier N, Cano A, De Lonlay P, Arnoux JB, Brassier A, et al. Individual and Family Determinants for Quality of Life in Parents of Children with Inborn Errors of Metabolism Requiring a Restricted Diet: A Multilevel Analysis Approach. J Pediatr. 2023;254:39\u201347.","journal-title":"J Pediatr"},{"issue":"3","key":"2390_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ddrr.1119","volume":"17","author":"SE Waisbren","year":"2013","unstructured":"Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013;17(3):260\u20138.","journal-title":"Dev Disabil Res Rev"},{"issue":"Suppl 1","key":"2390_CR32","first-page":"187","volume":"54","author":"H Ogutlu","year":"2022","unstructured":"Ogutlu H, Kasak M, Tutku Tabur S. Mitochondrial dysfunction in attention deficit hyperactivity disorder. Eur J Med. 2022;54(Suppl 1):187\u201395.","journal-title":"Eur J Med"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-026-02390-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-026-02390-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:02:50Z","timestamp":1783951370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12920-026-02390-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1186\/s12920-026-02390-x","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (IRB No. 2021\u2009\u2212\u20090434). Written informed consent was obtained from all participants or their legal guardians prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}